NovoCure Ltd — Director's Dealing 2019

Mar 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-03-01

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-01	Ordinary Shares	M	100000	$14.37	Acquired	333757	Direct
2019-03-01	Ordinary Shares	S	37282	$54.973	Disposed	296475	Direct
2019-03-01	Ordinary Shares	S	55815	$55.848	Disposed	240660	Direct
2019-03-01	Ordinary Shares	S	6903	$56.486	Disposed	233757	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-01	Options to Buy Ordinary Shares	$14.37	M	100000	Disposed	2025-02-23	Ordinary Shares (100000)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.

F2: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 37,282 shares in multiple trades at prices ranging from $54.37 to $55.36. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 55,815 shares in multiple trades at prices ranging from $55.37 to $56.36. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: On March 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,903 shares in multiple trades at prices ranging from $56.37 to $56.58. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F5: Fully vested and currently exercisable as of the date hereof.